FindTrial
Sign In

This study is based on estimation of a biomarker named Nt pro BNP produced by the cardiac cells in preterm newborns having a heart defect called patent ductus arteriosus.

Estimation of serum N-terminal peptide of Brain Natriuretic Peptide levels in preterm newborns with Patent Ductus Arteriosus (PDA) a one year hospital based prospective observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/04/051604
Enrollment
60
Registered
2023-04-13
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Q250- Patent ductus arteriosus

Interventions

Intervention1: Not applicable: Not applicable Control Intervention1: Comparing levels of Serum NT-ProBNP in preterm newborns less than 36weeks with PDA and without PDA: Comparing levels of Serum NT-Pr

Sponsors

Dr Abhoorvaa OC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All Preterm infants born before 36 weeks of gestation admitted in NICU undergoing echocardiography evaluation

Exclusion criteria

Exclusion criteria: Other congenital heart diseases Neonatal Sepsis Bronchopulmonary dysplasia Congenital anomalies/malformations Blleding tendency

Design outcomes

Primary

MeasureTime frame
Estimation of NT-pro BNP in preterm newborn with PDATimepoint: At baseline—

Secondary

MeasureTime frame
To correlate the levels of NT-pro BNP with hemodynamically significant PDA in preterm newbornsTimepoint: 1 week—

Countries

India

Contacts

Public ContactAbhoorvaa OC

Professor

manviveeresh@gmail.com7010295182

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026